NCT07424430Completed
Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 3392 (actual)
- First submitted
- 13 Feb 2026
- Start date
- 20 Feb 2026
- Primary completion date
- 28 Sept 2026
- Lead sponsor
- LMC Diabetes & Endocrinology Ltd.
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07424430
What you commit to
- Study type: Observational
- Participants enrolled: 3392
- From 20 Feb 2026 to the primary completion date, 28 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in a research study with an Investigational Product
- Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort)
Other illness
- Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA)
- Documented history or family history of medullary thyroid carcinoma
Lab values
- eGFR \< 15 mL/min/1.73m2 at index date
Other
- Clinical diagnosis of T2D (obesity cohort only)
- Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period
- Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)
Who the study is looking for
- T2D Cohort:
- A clinical diagnosis of T2D ≥ 1 year
- HbA1c ≥ 6.5% (pre-index date)
- Initiated semaglutide or other AHA(s) before January 1st, 2023\*
- Seen by an LMC endocrinologist in the last 18 months as of the query date
- ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date
- Informed data consent for their medical record data to be used for research purposes
- Obesity Cohort:
- 18 years or older
- BMI ≥ 27 kg/m2
- HbA1c \< 6.5% (pre-index date)
- Initiated semaglutide before January 1st, 2023\*
- Seen by an LMC endocrinologist in the last 18 months as of the query date
- ≥ one HbA1c value up to 6 months (± 90 days) prior to index date
- Informed data consent for their medical record data to be used for research purposes
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| LMC Diabetes & Endocrinology Ltd. Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.